Sildenafil in the treatment of erectile dysfunction in multiple sclerosis: Results of a questionnaire to patients and their partners

A. Ghezzi, S. Baldini, G. M. Malvestiti, V. Martinelli, E. Montanari, A. Savino, M. Zaffaroni, A. Zibetti

Research output: Contribution to journalArticlepeer-review

Abstract

Background. Sildenafil is an effective drug for erectile dysfunction (ED) of various causes, including neurological diseases. We evaluated the efficacy of sildenafil in an open collaborative study of patiens affected by multiple sclerosis (MS). Subjects and methods. We studied 40 patieents affected by MS (mean age 43.7±8.3 years, mean disease duration 10.3±6.9 years) complaining of ED for at least 6 months (mean duration of ED 3.8±2.1 years). ED was scored by the International Index of Erectile Function-5 (IIEF-5). Sildenafil was given at a fixed dose of 50 mg, taken 1 h before sexual activity. Results to treatment were evaluated after 8 administrations/ 3 months. The questionnaire, in a modified version, was administered to the patient's partner, too. Results and comment. Four patients had no sexual activity in the following 3 months and did not answer the questionnaire. The evaluation of results was performed in 36 patients. The mean basal score of the IIEF-5 was 11±4.7, ranging fron 6 to 18; ED was diagnosed if IIEF-5 score was

Original languageEnglish
JournalNeurological Sciences
Volume21
Issue number4 SUPPL.
Publication statusPublished - 2000

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Sildenafil in the treatment of erectile dysfunction in multiple sclerosis: Results of a questionnaire to patients and their partners'. Together they form a unique fingerprint.

Cite this